Impacts of clinicopathologic and operative factors on short-term and long-term survival in renal cell carcinoma with venous tumor thrombus extension: a multi-institutional retrospective study in Japan

Masanori Hirono, Mikio Kobayashi, Tomoyasu Tsushima, Wataru Obara, Nobuo Shinohara, Keiichi Ito, Masatoshi Eto, Tatsuya Takayama, Yasuhisa Fujii, Masaharu Nishikido, Go Kimura, Takeshi Kishida, Masayuki Takahashi, Noriomi Miyao, Yukio Naya, Takashige Abe, Tomoaki Fujioka, Kazuto Ito, Seiji Naito, Members of the Japanese Society of Renal Cancer, Masanori Hirono, Mikio Kobayashi, Tomoyasu Tsushima, Wataru Obara, Nobuo Shinohara, Keiichi Ito, Masatoshi Eto, Tatsuya Takayama, Yasuhisa Fujii, Masaharu Nishikido, Go Kimura, Takeshi Kishida, Masayuki Takahashi, Noriomi Miyao, Yukio Naya, Takashige Abe, Tomoaki Fujioka, Kazuto Ito, Seiji Naito, Members of the Japanese Society of Renal Cancer

Abstract

Background: Although the percentage of patients with renal cell carcinoma (RCC) extending into venous systems is unexpectedly high, the prognostic impact and independency of venous tumor thrombus-related factors on overall survival (OS) remain controversial. Furthermore, the prognostic impact of various clinicopathologic factors including tumor thrombus-related factors on OS may change with elapsed years after the intervention and also with follow-up duration of participants. The aim of the study is to explore independent and universal predictive preoperative and intraoperative clinicopathologic factors on OS in patients with RCC extending into venous systems using subgroup analysis in terms of restricted follow-up duration and yearly-based survivors.

Methods: Between 1980 and 2009, 292 patients diagnosed with RCC with venous tumor thrombus were retrospectively registered for this study. The prognostic impacts of various clinicopathologic and surgical treatment factors including levels of venous thrombus, venous wall invasion status and likelihood of aggressive cytoreductive operation, were investigated using Kaplan-Meier method and following multivariate Cox proportional hazards model for all patients and those still alive at 1, 2, and 3 years of follow-up. To investigate the impact of follow-up duration on the statistical analyses, multivariate logistic regression analyses were used to explore prognostic factors using restricted data until 1, 2, and 3 years of follow-up.

Results: The median follow-up duration was 40.4 months. The 5-year OS was 47.6%. Several independent predictive factors were identified in each subgroup analysis in terms of yearly-based survival and restricted follow-up duration. The presence of tumor thrombus invading to venous wall was independently related to OS in the full-range follow-up data and in survivors at 2 and 3 years of follow-up. Using restricted follow-up data until 1, 2, and 3 years of follow-up, many independent predictive factors changed with follow-up duration, but surgical category could be universal and independent predictive factors.

Conclusion: The most universal factors affecting improvement both in short-term and long-term survivals could be cytoreductive surgery and absence of venous wall invasion. It may mean that feasible aggressive cytoreductive operation following more reliable preoperative imaging for predicting venous wall invasion status would improve OS for patients with RCC extending into venous systems.

Figures

Figure 1
Figure 1
Overall survivals after operation or any interventions in all participants.
Figure 2
Figure 2
Overall survivals. (A) stratified by surgical categories (surgical category 1; radical nephrectomy and complete resection of thrombus without any metastases, surgical category 2 + 3; radical nephrectomy and complete resection of thrombus regardless of cytoreductive surgery at metastatic regions, surgical category 4 + 5; radical nephrectomy and incomplete resection of thrombus regardless of metastatic status or abandoned operation), (B) stratified by the status of renal vein (RV) or inferior vena cava (IVC) wall invasion.

References

    1. Pagano F, Dal Bianco M, Artibani W. et al.Renal cell carcinoma with extension into the inferior vena cava: problems in diagnosis, staging and treatment. Eur Urol. 1992;13:200–203.
    1. Casanova GA, Zingg EJ. Inferior vena caval tumor extension in renal cell carcinoma. Urol Int. 1991;13:216–218. doi: 10.1159/000282225.
    1. Hatcher PA, Anderson EE, Paulson DF. et al.Surgical management and prognosis of renal cell carcinoma invading the vena cava. J Urol. 1991;13:20–23.
    1. Hoehn W, Hermanek P. Invasion of veins in renal cell carcinoma - frequency, correlation and prognosis. Eur Urol. 1983;13:276–280.
    1. Klatte T, Pantuck AJ, Riggs SB. et al.Prognostic factors for renal cell carcinoma with tumor thrombus extension. J Urol. 2007;13:1189–1195. doi: 10.1016/j.juro.2007.05.134.
    1. Kim HL, Zisman A, Han KR. et al.Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol. 2004;13:588–591. doi: 10.1097/01.ju.0000104672.37029.4b.
    1. Al Otaibi M, Abou Youssif T, Alkhaldi A. et al.Renal cell carcinoma with inferior vena caval extension: impact of tumour extent on surgical outcome. BJU Int. 2009;13:1467–1470. doi: 10.1111/j.1464-410X.2009.08575.x.
    1. Wagner B, Patard JJ, Méjean A. et al.Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol. 2009;13:452–459. doi: 10.1016/j.eururo.2008.07.053.
    1. Blute ML, Leibovich BC, Lohse CM. et al.The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int. 2004;13:33–41. doi: 10.1111/j.1464-410X.2004.04897.x.
    1. Marshall VF, Middleton RG, Holswade GR. et al.Surgery for renal cell carcinoma in the vena cava. J Urol. 1970;13:414–420.
    1. Skinner DG, Colvin RB, Vermillion CD. et al.Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer. 1971;13:1165–1177. doi: 10.1002/1097-0142(1971)28:5<1165::AID-CNCR2820280513>;2-G.
    1. Skinner DG, Pfister RF, Colvin R. Extension of renal cell carcinoma into the vena cava: the rationale for aggressive surgical management. J Urol. 1972;13:711–716.
    1. Skinner DG, Pritchett TR, Lieskovsky G. et al.Vena caval involvement by renal cell carcinoma. Surgical resection provides meaningful long-term survival. Ann Surg. 1989;13:387–392. doi: 10.1097/00000658-198909000-00014.
    1. Ficarra V, Righetti R, D’Amico A. et al.Renal vein and vena cava involvement does not affect prognosis in patients with renal cell carcinoma. Oncology. 2001;13:10–15. doi: 10.1159/000055346.
    1. Glazer AA, Novick AC. Long-term follow up after surgical treatment for renal cell carcinoma extending into the right atrium. J Urol. 1996;13:448–450. doi: 10.1016/S0022-5347(01)66415-2.
    1. Sosa RE, Muecke EC, Vaughan ED Jr. et al.Renal cell carcinoma extending into the inferior vena cava: the prognostic significance of the level of vena caval involvement. J Urol. 1984;13:1097–1100.
    1. Bissada NK, Yakout HH, Babanouri A. et al.Long-term experience with management of renal cell carcinoma involving the inferior vena cava. Urology. 2003;13:9–92.
    1. Libertino JA, Zinman L, Watkins E Jr. Long-term results of resection of renal cell cancer with extension into inferior vena cava. J Urol. 1987;13:21–24.
    1. Moinzadeh A, Libertino JA. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same? J Urol. 2004;13:598–601. doi: 10.1097/01.ju.0000108842.27907.47.
    1. Tanaka M, Fujimoto K, Okajima E. et al.Prognostic factors of renal cell carcinoma with extension into inferior vena cava. Int J Urol. 2008;13:394–398. doi: 10.1111/j.1442-2042.2008.02017.x.
    1. Zisman A, Wieder JA, Pantuck AJ. et al.Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol. 2003;13:909–916. doi: 10.1097/01.ju.0000045706.35470.1e.
    1. Haferkamp A, Bastian PJ, Jakobi H. et al.Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term follow up. J Urol. 2007;13:1703–1708. doi: 10.1016/j.juro.2007.01.039.
    1. Ficarra V, Novara G, Iafrate M. et al.Proposal for reclassification of the TNM staging system in patients with locally advanced (pT3-4) renal cell carcinoma according to the cancer-related outcome. Eur Urol. 2007;13:722–729. doi: 10.1016/j.eururo.2006.07.010.
    1. Thompson RH, Leibovich BC, Cheville JC. et al.Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a? J Urol. 2005;13:918–921. doi: 10.1097/01.ju.0000153419.98715.24.
    1. Moch H, Artibani W, Delahunt B. et al.Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol. 2009;13:636–643. doi: 10.1016/j.eururo.2009.06.036.
    1. Thompson RH, Leibovich BC, Cheville JC. et renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? J Urol. 2005;13:1218–1221. doi: 10.1097/01.ju.0000173942.19990.40.
    1. Leibovich BC, Cheville JC, Lohse CM. et al.Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved? J Urol. 2005;13:716–719. doi: 10.1097/01.ju.0000151830.27750.d2.
    1. Ficarra V, Galfano A, Guillé F. et al.A new staging system for locally advanced (pT3-4) renal cell carcinoma: a multicenter European study including 2,000 patients. J Urol. 2007;13:418–424. doi: 10.1016/j.juro.2007.03.104.

Source: PubMed

3
Suscribir